Abstract: The contribution of this paper is to explore how in-situ co-design of indoor spaces (e.g. building) of Location-based Mobile Games could be handle, by describing the learned lessons on this topic. This paper presents a conceptual framework for in-situ co-design of indoor spaces on Location-based Mobile Games to assist to carry out this kind of experience using useful resources (as Design Thinking's resources). An experience of in-situ co-design for an indoor space on a Location-based Mobile Game is presented using this framework; for some phases an authoring tool was used which allows in-situ co-design of relevant locations for an application. Based on this experience, the authoring tool was extended to create a specific kind of Location-based Mobile Game. This paper presents this extension along with a proof of concept that shows how an in-situ co-designed game created by this extension was used by end-users.

Resumen: El aporte de este trabajo es explorar cómo abordar experiencias de co-diseño in-situ de Juegos Móviles basados en posicionamiento en espacios cerrados (por ejemplo, un edificio), describiendo las lecciones aprendidas sobre esta temática. En este trabajo se presenta un framework conceptual para el co-diseño in-situ de Juegos Móviles basados en posicionamiento para espacios cerrados con el objetivo de ayudar a los facilitadores a abordar este tipo de experiencias con recursos útiles (por ejemplo, recursos de Design Thinking). Usando este framework, se presenta una experiencia de co-diseño in-situ de un Juego Móvil basado en posicionamiento en un espacio cerrado; para algunas etapas se utilizó una herramienta de autor que permite co-diseñar in-situ cuáles son los lugares relevantes para una aplicación. A partir de esta experiencia, se extendió la herramienta de autor para poder crear un tipo particular de Juego Móvil basado en posicionamiento. En este trabajo se presenta esta extensión junto con una prueba de conceptos que muestra cómo un juego co-diseñado in-situ con esta extensión fue usado por usuarios finales.

The objective of this multicenter prospective study was to determine the clinical efficacy and toxicity of a polychemotherapeutic third generation regimen, VACOP-B, with or without radiotherapy as front-line therapy in aggressive localized non-Hodgkin's lymphoma. Ninety-three adult patients (47 males and 46 females, median age 45 years) with aggressive localized non-Hodgkin's lymphoma, 43 in stage I and 50 in stage II (non-bulky), were included in the study. Stage I patients received VACOP-B for 6 weeks plus involved field radiotherapy and stage II patients received 12 weeks VACOP-B plus involved field radiotherapy on residual masses. Eighty-six (92.5%) achieved complete remission and 4 (4.3%) partial remission. Three patients (3.2%) were primarily resistant. Ten-year probability of survival, progression-free survival and disease-free survival were 87.3, 79.9 and 83.9%, respectively. Eighty-four patients are surviving at a median observation time of 57 months (range: 6-126). Statistical analysis showed no difference between stages I and II in terms of response, ten-year probability of survival, progression-free survival or disease-free survival. Side effects and toxicity were negligible and were similar in the two patient groups. The results of this prospective study suggest that 6 weeks of VACOP-B treatment plus radiotherapy may be the therapy of choice in stage I aggressive non-Hodgkin's lymphoma. Twelve weeks of VACOP-B treatment with or without radiotherapy was shown to be effective and feasible for stage II. These observations need to be confirmed by a phase III study comparing first and third generation protocols in stage I-II aggressive non-Hodgkin's lymphoma.

Thrombocytopenia is an important and common hematological abnormality in patients with HIV-1/HCV coinfection. Splenomegaly is a frequent finding in these patients and usually causes hypersplenism and thrombocytopenia. We analyzed the clinical results of a minimal invasive treatment (splenic artery embolization) for thrombocytopenia secondary to hypersplenism and refractory to other therapies in two hemophiliac patients, HIV seropositive and with cirrhosis due to chronic HCV infection. The results suggest that splenic artery embolization is a safe, relatively atraumatic and effective method for the treatment of splenomegaly and hypersplenism in selected patients with HIV-1/HCV coinfection.

La trombocitopenia es una anomalía usual e importante en pacientes con coinfección por HIV-1/HCV. La esplenomegalia es un hallazgo frecuente en estos pacientes y, usualmente, causa hiperesplenismo y trombocitopenia. Analizamos los resultados clínicos de un método invasivo mínimo (embolización de la arteria esplénica) para el tratamiento de la trombocitopenia secundaria al hiperesplenismo y refractaria a otras terapias en dos pacientes hemofílicos, infectados por el HIV-1 y con cirrosis causada por la infección crónica por HCV. Estos resultados sugieren que la embolización de la arteria esplénica es un método seguro, poco traumático y efectivo para el tratamiento de la esplenomegalia y el hiperesplenismo en pacientes con coinfección por HIV-1/HCV.